Genmab — Marts 2019
-
Genmabs Darzalex-kombination får sløj anbefaling af britisk prisforhandler
Det britiske prioriteringsinstitut NICE har anbefalet Genmabs Darzalex i kombination med to andre midler, men kun gennem et finansieringsprogram for behandlinger med usikre kliniske data.
(medwatch.dk)
-
God formiddag
-
Det vi oplever i aktien i disse dage ligner almindelig sund basedannelse.
-
Det sker efter en stigning på 15% på den seneste måned. Det virker nu meget sundt iflg min indre lærebog.
-
Heroppe kalde vi det at træde vande..;-)
-
Det bliver man træt i benene af. Ikke meget fast base i det.
-
-
Man skal bare ha´ goe´ ben Helge..:-D
-
-
-
Enig Legolas23.
-
Genmab er med her: http://www.proinvestor.com/investornyt/602697/ny-aktie-i-modelportefoljen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind